MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia by Kerry J et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Kerry J, Godfrey L, Repapi E, Tapia M, Blackledge NP, Ma H, Ballabio E, 
O'Byrne S, Ponthan F, Heidenreich O, Roy A, Roberts I, Konopleva M, Klose RJ, 
Geng H, Milne TA.  
MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-
Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.  
Cell Reports 2017, 18(2), 482-495. 
 
 
Copyright: 
© 2016 The Authors. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/by/4.0/). 
DOI link to article: 
https://doi.org/10.1016/j.celrep.2016.12.054  
Date deposited:   
16/05/2017 
ArticleMLL-AF4 Spreading Identifies Binding Sites that Are
Distinct from Super-Enhancers and that Govern
Sensitivity to DOT1L Inhibition in LeukemiaGraphical AbstractHighlightsd MLL-AF4 binding requires an unmethylated CpG (uCpG)
island and Menin
d MLL-AF4 and Menin can spread into the gene body of some
targets
d Spreading targets are highly transcribed and have an
aberrant chromatin signature
d Spreading of MLL-AF4 is a predictor of sensitivity to DOT1L
inhibitorsKerry et al., 2017, Cell Reports 18, 482–495
January 10, 2017 ª 2017 The Author(s).
http://dx.doi.org/10.1016/j.celrep.2016.12.054Authors
Jon Kerry, Laura Godfrey, Emmanouela
Repapi, ..., Robert J. Klose, Huimin Geng,
Thomas A. Milne
Correspondence
thomas.milne@imm.ox.ac.uk
In Brief
Translocations of the MLL gene produce
fusion proteins such as MLL-AF4 that
cause poor-prognosis leukemias. Kerry
et al. show that MLL-AF4 can spread into
the gene body of some target genes.
Spreading targets have an aberrant
chromatin signature and are sensitive to
DOT1L inhibitors.Accession NumbersGSE83671
Cell Reports
ArticleMLL-AF4 Spreading Identifies Binding Sites that
Are Distinct from Super-Enhancers and that
Govern Sensitivity to DOT1L Inhibition in Leukemia
Jon Kerry,1 Laura Godfrey,1 Emmanouela Repapi,2 Marta Tapia,1 Neil P. Blackledge,3 Helen Ma,4 Erica Ballabio,1
Sorcha O’Byrne,5 Frida Ponthan,6 Olaf Heidenreich,6 Anindita Roy,5 Irene Roberts,1,5 Marina Konopleva,4
Robert J. Klose,3 Huimin Geng,7 and Thomas A. Milne1,8,*
1MRC, Molecular Haematology Unit, NIHR Oxford Biomedical Research Centre Programme
2Computational Biology Research Group, Weatherall Institute of Molecular Medicine
University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK
3Laboratory of Chromatin Biology and Transcription, Department of Biochemistry, University of Oxford, Oxford OX1 3QU, UK
4Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
5Department of Paediatrics, University of Oxford, Children’s Hospital, John Radcliffe, Oxford OX3 9DU, UK
6Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne NE1
7RU, UK
7Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA
8Lead Contact
*Correspondence: thomas.milne@imm.ox.ac.uk
http://dx.doi.org/10.1016/j.celrep.2016.12.054SUMMARY
Understanding the underlying molecular mecha-
nisms of defined cancers is crucial for effective
personalized therapies. Translocations of the
mixed-lineage leukemia (MLL) gene produce fusion
proteins such as MLL-AF4 that disrupt epigenetic
pathways and cause poor-prognosis leukemias.
Here, we find that at a subset of gene targets,
MLL-AF4 binding spreads into the gene body
and is associated with the spreading of Menin bind-
ing, increased transcription, increased H3K79
methylation (H3K79me2/3), a disruption of normal
H3K36me3 patterns, and unmethylated CpG regions
in the gene body. Compared to other H3K79me2/3
marked genes, MLL-AF4 spreading gene expression
is downregulated by inhibitors of the H3K79 methyl-
transferase DOT1L. This sensitivity mediates syner-
gistic interactions with additional targeted drug
treatments. Therefore, epigenetic spreading and
enhanced susceptibility to epidrugs provides a po-
tential marker for better understanding combination
therapies in humans.
INTRODUCTION
Translocations of the mixed-lineage leukemia (MLL) gene pro-
duce over 120 different MLL fusion proteins (MLL-FPs) that
cause aggressive acute leukemias, the most common one being
the MLL-AF4 fusion (Ballabio and Milne, 2012; Meyer et al.,
2013). Despite much progress in the treatment of childhood leu-
kemias, infants carrying MLL rearrangements have a very poor482 Cell Reports 18, 482–495, January 10, 2017 ª 2017 The Author(s
This is an open access article under the CC BY license (http://creativeprognosis (Pui et al., 2011); thus, improving therapies forMLL-FP
patients remains an unmet need. Because MLL-FPs are consid-
ered to be the main drivers of leukemogenesis, their function
regulating downstream target genes is key to understanding
MLL-rearranged (MLLr) leukemias and for designing targeted
therapies.
MLL-FPs retain several domains (Figure 1A) including a CXXC
domain that binds specifically to unmethylated CpG (uCpG) DNA
(Birke et al., 2002), interaction sites with the multiple endocrine
neoplasia type 1 (Menin) (Yokoyama et al., 2005) and lens epithe-
lium-derived growth factor (LEDGF) proteins (Yokoyama and
Cleary, 2008), and an interaction with the polymerase-associ-
ated factor protein complex (PAFc) (Milne et al., 2010; Muntean
et al., 2010). Recruitment of MLL-FPs to gene targets is thought
to be controlled byMenin, LEDGF, and PAFc interactions as well
as CXXC binding to uCpGs (Milne et al., 2010; Muntean et al.,
2010; Okuda et al., 2014; Yokoyama and Cleary, 2008; Yo-
koyama et al., 2005). Supporting this, a minimalMLL-FP contain-
ing just the PWWP domain of LEDGF, the CXXC domain of MLL,
and the transactivation domain of the fusion partner can trans-
form bone marrow progenitors and recapitulate MLL-FP binding
at a few select genes (Okuda et al., 2014). However, a minimal
CXXC domain can be recruited to the HoxA9 locus in the
absence of a Menin/LEDGF interaction (Milne et al., 2010),
although others have suggested that the CXXC domain has no
role in recruitment and instead protects uCpG sites frommethyl-
ation (Risner et al., 2013). Recent data also suggest that Menin is
unimportant for wild-typeMLL (Borkin et al., 2015; Li et al., 2013),
whereas LEDGF is required for MLL but not MLL-FP recruitment
(Zhu et al., 2016). Thus, it still remains an open question exactly
how MLL-FPs are recruited to particular gene targets.
MLL-FP recruitment is associated with increased histone 3
lysine 79 di- and tri-methylation (H3K79Me2/3) at target genes,
an epigenetic mark associated with gene activation (Bernt).
commons.org/licenses/by/4.0/).
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et al., 2011; Guenther et al., 2008; Krivtsov et al., 2008; Milne
et al., 2005). H3K79Me2/3 levels are controlled by the disruptor
of telomeric silencing 1-like (DOT1L) protein (Jones et al., 2008).
In MLL-FP leukemias, DOT1L directly interacts with AF9 or ENL
(Biswas et al., 2011; Mueller et al., 2007), and can be mis-tar-
geted to MLL-FP-bound genes where it is associated with inap-
propriate activation of gene expression (Milne et al., 2005) (Fig-
ure 1B). A recent study analyzing MLL-ENL binding suggests
that there are two distinct classes of binding: proximal (50) or
distal (30) to the transcription start site, with proximal binding be-
ing particularly sensitive to DOT1L inhibition (Garcia-Cuellar
et al., 2016). MLL-AF4 can also bind in broad regions of up to
100 kb that correlate with large domains of H3K4me3 (Guenther
et al., 2008) andMLL-AF9 transformedmouse bonemarrow cells
display H3K79me2 peaks with a similar wide spatial distribution
(Bernt et al., 2011). Despite all this work, there is no current
consensus on whether the main activity of MLL-FPs is the
recruitment of DOT1L or whether different binding patterns of
MLL-FPs are associated with distinct functional outcomes.
Here, we reveal a strong co-dependent relationship between
MLL-AF4 and Menin binding at a small number of target genes
containing uCpGs. At a subset of these gene targets, we observe
MLL-AF4 and Menin spreading that is bookended by uCpGs.
These spreading targets are distinct from super-enhancers, are
associated with high levels of gene transcription, have an aber-
rant H3K79me2/H3K36me3 signature, and are predictive of a
poor overall survival in patients with acute lymphoblastic leuke-
mia (ALL). These gene targets also display a remarkable depen-
dence on H3K79me2 and the fusion protein for their sustained
expression in leukemia. Together, this work shows that MLL-FP
spreading occurs at genes important in MLL leukemogenesis
and has the potential to act as a biomarker for therapeutic
response.
RESULTS
MLL-AF4 Binds Exclusively to a Subset of uCpGs
Using MLL(N) and AF4(C) chromatin immunoprecipitation
sequencing (ChIP-seq) in the humanMLL-AF4 SEM cell line (Fig-
ure 1C), we identified 4,427 peaks and a gene set of 2,597 unique
genes (Table S1). MLL(N) ChIP-seq replicates had 81% peaks in
common (Figure 1D), which identified 96.4% promoter-bound
MLL(N) gene targets from our original ChIP-seq dataset (Table
S1, ‘‘Overlaps’’). This gave us high confidence in the reproduc-
ibility of our gene target identification. To test the specificity ofFigure 1. MLL-AF4 Is Recruited Exclusively to uCpG Regions Bound b
(A) Schematic showing MLL and MLL fusion protein interaction sites.
(B) Schematic showing the MLL-AF4 core complex.
(C) Example ChIP-seq, Bio-CAP-seq, and ATAC-seq tracks in SEM cells.
(D) Venn diagram showing overlap between two biological replicates of MLL(N) C
(E) Heatmap showing ChIP-seq, Bio-CAP-seq, and ATAC-seq reads at all 4,427M
per 107 reads.
(F) Venn diagram showing overlap between MLL-AF4 binding sites and uCpG re
(G) Heatmap showing MLL(N), AF4(C), and Menin ChIP-seq reads at all MLL-AF4
(H) Venn diagram showing overlap between MLL-AF4, PAF1, and Menin binding
(I and J) Scatterplot showing a strong correlation (r2 = 0.96) between MLL(N) a
correlation between Menin and CFP1 (r2 = 0.27) at all CFP1 peaks (J) in SEM ce
See also Figure S1.
484 Cell Reports 18, 482–495, January 10, 2017theMLL-AF4 target set, we performedMLL-AF4 small interfering
RNA (siRNA) knockdowns coupled with nascent RNA
sequencing (RNA-seq) (Figure S1A) andMLL-AF4ChIP-seq (Fig-
ure S1B). Our MLL-AF4 gene target set was significantly down-
regulated at most genes (Figure S1A, p < 0.01, Mann-Whitney U
test) and lost MLL-AF4 ChIP-seq signal at 85% of target gene
promoters (Figures S1B and S1C). Among the 15% of MLL-AF4
gene targets with no reduced ChIP-seq signal, one-third showed
a significant change in gene expression following MLL-AF4
knockdown (Figure S1C). This suggests that these targets are
also directly regulated by MLL-AF4, even though they consist
primarily of promoters with a low MLL(N) ChIP-seq signal
(Figure S1D).
If the CXXC domain is essential for MLL-AF4 recruitment, we
would expect all MLL-AF4 binding sites to occur at regions of
uCpGs. To test this, we used a biotinylated CXXC affinity purifi-
cation (Bio-CAP) assay (Blackledge et al., 2012) for high-sensi-
tivity detection of regions of uCpG dinucleotides in SEM cells,
combined with an assay for transposase-accessible chromatin
sequencing (ATAC-seq) (Buenrostro et al., 2013) to identify
regions of open chromatin (Figure 1C). Similar to results using
non-methylated CpG/methylated-CpG island recovery assay
sequencing (CIRA/MIRA-seq) with MLL-AF6 (Okuda et al.,
2014), all MLL-AF4 binding occurred at open uCpG regions (Fig-
ure 1E) with the highest uCpG enrichment occurring at the cen-
ter of MLL-AF4 binding sites (Figure S1E). However, MLL-AF4
binding occurred at only 20% of uCpG sites (Figure 1F), indi-
cating that open uCpG sites alone are not sufficient for MLL-
AF4 recruitment. The Venn diagram (Figure 1F) shows a few
MLL-AF4 sites that do not overlap with uCpGs, but it is clear
from the heatmap that all MLL-AF4 binding sites occur at
uCpG sites. The discrepancy is likely due to the reduced
sensitivity of peak-calling programs used for the Venn diagram
analysis.
To determine whether other CXXC domain-containing pro-
teins (‘‘CXXC proteins’’ from now on) are also restricted to only
a proportion of uCpG sites, we performed ChIP-seq for CFP1
(a CXXC protein member of the SET1 complex associated with
gene activation), and KDM2B (a CXXC protein involved in the
recruitment of the polycomb group repressive complex [PRC]
[Farcas et al., 2012]), in SEM cells (Figure 1C). In contrast to
MLL-AF4, CFP1 and KDM2B bound more ubiquitously to
uCpG sites, being found at 50% and 89% of all uCpG sites,
respectively (Figure S1F). Because the CXXC domains of
MLL-AF4, CFP1, and KDM2B are highly related (Long et al.,y Menin
hIP-seq.
LL-AF4 binding sites in SEM cells. Scale bar represents tags per base pair (bp)
gions (Bio-CAP-seq and ATAC-seq) in SEM cells.
binding sites in SEM cells. Scale bar as in (E).
sites in SEM cells.
nd Menin ChIP-seq signal at all MLL-AF4 peaks (I) in SEM cells and a weak
lls.
2013), the differences in the number of bound uCpGs may be
due to other protein interactions influencing recruitment.
Genome-wide Recruitment of Menin Mirrors that of
MLL-AF4
To investigate whether MLL-AF4-specific interactions contribute
to uCpG binding, we analyzed two complexes thought to be
involved in MLL-FP recruitment: Menin/LEDGF and PAFc (Fig-
ures 1A–1C). Except for a very few Menin binding sites (Fig-
ure 1G, very bottom of heatmap), we found that almost all
MLL-AF4 binding sites overlap with detectable Menin binding
(Figure 1G). Many MLL-AF4 binding sites had only low levels of
detectable Menin (Figure 1G), and thus strict peak-calling pa-
rameters produce an MLL-AF4/Menin overlap at only a subset
of binding sites (Figure 1H). However, when MLL-AF4 binding
sites were separated into either high or low Menin binding, we
saw a direct relationship between levels of Menin binding and
levels of MLL-AF4 binding (Figure S1G). Furthermore, a direct
comparison of MLL(N) and Menin ChIP-seq reads at MLL-AF4
binding sites showed a significantly strong positive correlation
(r2 = 0.96) (Figure 1I), whereas neither KDM2B nor CFP1 binding
correlated withMenin (Figures 1J and S1H). Thus, an association
with Menin represents a feature that may serve to restrict
MLL-AF4 recruitment to a particular subset of uCpG sites.
ChIP-seq on two members of PAFc, PAF1 and LEO1 (Fig-
ure 1C), overlapped with less than one-half of MLL-AF4 binding
sites, and 4,892 (78%) of PAFc binding sites had no MLL-AF4
binding (Figure S1I). Thus, compared to Menin binding, there is
very little evidence for an MLL-AF4:PAF1 association genome-
wide (Figure 1H), but it is possible that PAFc is necessary for
recruitment only at select sites.
The Menin:MLL-AF4 Interaction Is Sufficient for
Recruitment
Todirectly test the functionality of the interactions betweenMenin,
MLL-AF4, and potentially PAFc, we used a Tet-repressor (TetR)
system (see Figure 2A legend) previously designed to investigate
the recruitment of PRC proteins (Blackledge et al., 2014). Using
ChIP-qPCR, we detected binding of Menin but not PAF1 in the
presence of TetR-MLL-AF4 but not the TetR-only control (Fig-
ure 2B, left versus right panel), and recruitment was lost upon
treatment with doxycycline (Figure 2B, left panel, red line). Recip-
rocal experiments using TetR-Menin- and TetR-PAF1-expressing
mESC lines transiently transfected with MLL-AF4 produced
equivalent results (Figures S2A and S2B). Despite being able to
recruit other members of PAFc, TetR-PAF1 was not sufficient to
recruit MLL-AF4 (Figures S2B and S2C). Expression of different
constructs was confirmed with either western blot or qPCR (Fig-
ures S2D and S2E). It has been recently shown that knockdowns
of LEDGF sometimes lead to an increase in MLL-FP binding (Zhu
et al., 2016). Similar to Zhu et al., we noticed a slight increase in
MLL(N) ChIP at TetO in the presence of Ledgf siRNA (Figures
S2F andS2G), althoughwewereonly able to achieve a 30% Ledgf
knockdown at the RNA level (Figure S2F).
Our results so far support previous models suggesting that
Menin recruits MLL-FPs (Yokoyama et al., 2005, 2010), and con-
trasts with previous reports that suggest that PAFc can recruit
MLL-FPs (Milne et al., 2010; Muntean et al., 2010) (Figure 2C).The TetR assay does not establish directionality of these interac-
tions; thus, it is also possible that MLL-FPs can recruit Menin
(Caslini et al., 2007), or that the two proteins co-stabilize each
other, as has recently been suggested for LEDGF and wild-type
MLL (Zhu et al., 2016). In addition, it is possible that a relatively
weak MLL-AF4:PAFc interaction is stabilized by other interac-
tions when it occurs at active genes. To explore these issues
further, we performed MLL-AF4, PAF1, or Menin siRNA knock-
downs in SEM cells (Figures 2D–2H). MLL-AF4 knockdowns
have a strong effect on the binding of Menin to gene targets (Fig-
ure 2Gi) and a moderate but detectable effect on PAF1 binding
(Figure 2Hi). Menin knockdowns reduce both MLL-AF4 and
PAF1 binding to gene targets (Figures 2E–2Hii), whereas two
different PAF1 siRNAs produce a similar result in that they
reduce Menin binding slightly but have little effect on MLL-AF4
except at theHOXA9 locus (Figures 2E–2Hiii and S2H). Together,
these data show that there is a complex co-recruitment relation-
ship betweenMLL-AF4 andMenin, and that PAF1 does not have
a major role in recruiting MLL-AF4 to most gene targets. Howev-
er, MLL-AF4 either directly or indirectly, has a role in maintaining
stable PAF1 binding at specific gene targets. To analyze
MLL-AF4 function in further detail, we next tried to determine
whether MLL-AF4 displayed distinct binding profiles at different
subsets of genes.
Spreading of MLL-AF4 Marks a Subset of Highly
Expressed Genes
An analysis of MLL-AF4 binding profiles revealed two patterns of
binding. The majority of MLL-AF4 binding sites displayed narrow
binding at the promoter and a normal pattern of H3K79me2 and
H3K36me3 (Figure 3A).We also occasionally observedMLL-AF4
spreading greater than 4 kb into the gene body without
exceeding the end of the gene, and this was associated with
H3K79me2 spreading and a reduction or loss of H3K36me3
throughout the gene body (Figure 3B). Spreading was observed
at 149 (3.4%) MLL-AF4 gene target isoforms (117 unique gene
targets) in SEM cells (Figure S3A; Table S2). A Gene Ontology
analysis revealed that spreading occurred at genes involved in
hematopoiesis as well as lymphocyte activation and differentia-
tion, showing that it could have a role in leukemia initiation or
maintenance (Figure S3B). We confirmed that spreading was
specific to MLL-AF4 using MLL-AF4 siRNA knockdowns fol-
lowed by ChIP-qPCR in regions of spreading at specific targets
(Figure S3C). Spreading is reminiscent of broad MLL-AF4 bind-
ing domains at sites of broad H3K4me3 (Guenther et al., 2008),
although we found that there was less than a 50% overlap be-
tween our spreading dataset and the MLL-AF4 target set origi-
nally identified by Guenther et al. (Figure S3D).
To test whether MLL-AF4 spreading was a marker of signifi-
cant functional activity, we analyzed nascent RNA-seq data
and found that spreading MLL-AF4 targets showed significantly
higher expression compared to targets of non-spreading
MLL-AF4, or active gene targets bound by CFP1 (p < 0.0001,
two-tailed Mann-Whitney U test; Figure 3C). Spreading targets
were also highly enriched for H3K79me2 at the 50 end of the
gene compared to non-spreading MLL-AF4 or non-MLL-AF4
targets (Figure 3D). The increased enrichment of H3K79me2
along with its spread into the gene body, strongly suggestsCell Reports 18, 482–495, January 10, 2017 485
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Figure 2. The MLL-AF4:Menin Interaction Is
Sufficient but Not Necessary for Recruit-
ment
(A) The Tet-repressor (TetR) recruitment system.
An array of Tet-operator (TetO) sequences was
centrally inserted into a BAC lacking known pro-
moter, enhancer, or uCpG features, and the BAC
was inserted into chromosome 8 of mouse em-
bryonic stem cells (mESCs) (Blackledge et al.,
2014). Proteins of interest fused to the TetR can be
anchored at the TetO array. The TetR-TetO inter-
action can be disrupted with doxycycline treat-
ment, allowing one to test whether recruitment of a
specific protein is dependent on the continuous
presence of a particular TetR fusion.
(B) ChIP-qPCR showing the binding of TetR-MLL-
AF4 (using FS2 [TetR] and MLL(N) antibody), Me-
nin, and PAF1 in TetO mESCs transfected with
TetR-MLL-AF4 (left panel) and in TetR-only control
mESCs (right panel). Error bars represent the SD of
two biological replicates. Red line, with doxycy-
cline.
(C) The TetR experiments indicate that there is
a strong interaction between MLL-AF4 and
Menin and an undetectable interaction between
MLL-AF4 and PAF1.
(D) SEM cells were treated with MLL-AF4, Menin,
or PAF1 siRNAs, and individual representative
western blots from the experiments in E–H are
shown.
(E–H) MLL-N (E), AF4-C (F), Menin (G), and PAF1
(H) ChIP in control (black bars) and siRNA-treated
(gray bars) SEM cells as follows: column i, MLL-
AF4 siRNA; column ii, Menin siRNA; and column iii,
PAF1 siRNA. Note that the control samples are the
same between PAF1#1 siRNA and PAF1#2 siRNA
(see Figure S2H) experiments as these were per-
formed in parallel. Error bars represent the SD of at
least three biological replicates.
See also Figure S2.
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Figure 3. MLL-AF4 Spreading Marks a Sub-
set of Highly Expressed Genes
(A and B) Example ChIP-seq tracks showing pro-
moter-restricted (A) or spreading (B) of MLL-AF4,
H3K79me2, and H3K36me3 in SEM cells.
(C) Box-and-whisker plot showing the median and
interquartile (IQ) range of gene expression of
spreading MLL-AF4 gene targets (n = 149)
compared to non-spreading MLL-AF4 targets (n =
2,878) and CFP1 targets (n = 6,147). Gene
expression, normalized to GAPDH expression, is
derived from four biological replicates of nascent
RNA-seq in SEM cells. ****p < 0.0001, two-tailed
Mann-Whitney U test.
(D) Composite binding plot of H3K79me2 ChIP-
seq reads at the TSS of gene targets of spreading
MLL-AF4 (red), non-spreading MLL-AF4 (blue),
and non-MLL-AF4 targets that are marked by
H3K79me2 (green).
(E and F) Heatmap expression data showing
overexpression of 79% (E, COG P9906 patients
[Harvey et al., 2010]) or 64% (F, ECOG 2993 pa-
tients [Geng et al., 2012]) of SEM spreading targets
in MLL patients (MLLr) compared to the ALL pa-
tient subsets indicated.
(G and H) Super-PC analysis (Bair and Tibshirani,
2004) using the spreading-gene target list showing
relapse-free survival (RFS) of ALL patients (G,
COG P9906 [Harvey et al., 2010]) and overall sur-
vival (OS) of ALL patients (H, ECOG 2993 [Geng
et al., 2012]) classified by either high- or low-risk
scores computed using the spreading MLL-AF4
gene targets in a super-PC model; see Supple-
mental Experimental Procedures, Survival Anal-
ysis, for details.
See also Figure S3.that the H3K79me2 pattern observed is a consequence of
spreading MLL-AF4.
Because broad MLL-FP binding domains have been
observed previously (Bernt et al., 2011; Guenther et al., 2008),
one possibility is that spreading identifies bona fide MLL-AF4
target genes, whereas non-spreading peaks represent wild-
type MLL and AF4 co-bound sites. To test this, we separated
the MLL-AF4 siRNA nascent RNA-seq and ChIP-seq datasets
(Figures S1A–S1D) into spreading and non-spreading target
sets. We found that almost all spreading and non-spreading tar-
gets are bound by MLL-AF4, but spreading targets are more
likely to be downregulated by a loss of MLL-AF4 (Figures S3E
and S3F). A recently generated FLAG tagged MLL-Af4 ChIP-
seq experiment in CD34+ cord blood cells (Lin et al., 2016) al-Cell Rlowed us to unambiguously identify
MLL-Af4 binding sites in a primary trans-
formed cell. FLAG-MLL-Af4 ChIP-seq
identified almost 3,000 MLL-Af4 gene
targets, similar to the number we ob-
tained in SEM cells (Lin et al., 2016).
FLAG-MLL-Af4 binding could be divided
into both spreading and non-spreading
targets, about 40%–50% of which over-
lapped with MLL-AF4 targets in SEMcells (Figures S3G–S3I). Taken together, this suggests that
MLL-AF4 can display both spreading and non-spreading bind-
ing patterns, but spreading gene targets are less common and
are more significantly associated with a dependence on
MLL-AF4 for their activation.
In order to better understand the significance of our spreading
target set, we analyzed the expression profile of SEM spreading
targets in two different patient cohorts and found that 64%–79%
of SEM spreading targets are overexpressed in MLLr ALL pa-
tients (Figures 3E and 3F). Using a super-PC analysis (Bair and
Tibshirani, 2004), we also found that there is a signature within
the spreading target set that is predictive of a poor prognosis
in patients (Figures 3G and 3H). Thus, MLL-AF4 spreading tar-
gets also have clinical significance in patients.eports 18, 482–495, January 10, 2017 487
Spreading Is Common among MLL Fusion Proteins but
Not Wild-Type MLL
Because spreading is an important feature of MLL-AF4 binding,
we investigated how common spreading is for other MLL-FPs.
MLL(N) ChIP-seq in theMLL-AF6 cell lineML-2 detects the fusion
protein unambiguously due to a deletion of the wild-type MLL
allele. Spreading for MLL-AF6 was observed at 47 (43.1%) gene
target isoforms (Figure 4A; Table S3), and similar to MLL-AF4,
these spreading targets displayed a significant increase in
H3K79Me2 compared to non-spreading MLL-AF6 targets (Fig-
ure 4B). The high percentage of spreading peaks within the
MLL-AF6 set is due to the lownumber (109) of totalMLL-AF6bind-
ing events in ML-2 cells. Using MLL(N) ChIP-seq, spreading was
also observed in MV4;11 (MLL-AF4), KOPN-8 (MLL-ENL), and
THP-1 (MLL-AF9) MLLr cell lines (Figures 4C and 4D; Table S1).
ER-tagged MLL-ENL (Garcia-Cuellar et al., 2016), biotin-tagged
MLL-AF9 (Bernt et al., 2011), MLL-AF4 in MV4;11 cells (Zhu
et al., 2016), MLL-AF4 in patient cells (this study), and FLAG-
MLL-Af4 in CD34+ cells (Lin et al., 2016) also displayed spreading
(Figures4E, 4F, andS4A–S4E). The spreadingpattern ofMLL-AF4
in SEM cells often closely resembles the spreading pattern of
MLL-AF4 in patient cells or in FLAG-MLL-Af4 cells at common
gene targets (Figures S4D and S4E), suggesting there may be a
commonmechanism for spreadingamong thesediversesamples.
Importantly, wild-type MLL spreading is not observed in non-
MLLr leukemia cell lines (RCH-ACV or CCRF-CEM), at wild-type
MLL binding sites in SEM cells (Figures 4C and 4D), or for wild-
type MLL(C) in MV4;11 cells (Zhu et al., 2016) (Figure S4C).
MLL-AF4 displays spreading in primary patient cells, but there
wasnowild-typeMLL spreading in the relevant normal humanhe-
matopoietic cells from either cord blood (CB) or second-trimester
fetal bone marrow (FBM) (Figures 4E, 4F, S4A, and S4D). These
results show spreading is specifically associated with MLL-FPs.
Some Individual Spreading Gene Targets Have Altered
Gene Expression, Reduced DNA Methylation Patterns,
and Individual Poor Prognoses in Patients
To better understand the clinical significance of individual
spreading targets, we analyzed nine common targets from five
MLLr leukemia cell lines (Figure 4G; Tables S1 and S4). High
expression ofARID2, JMJD1C,MBNL1,MEF2C, orRUNX2 alone
is associated with at least one indicator of poor prognosis in ALL
patients (Table S4), and CPEB2, MBNL1, RUNX2, and ZEB2 are
all specifically overexpressed in MLL-FP leukemias (Figures 4H
and S5A; Table S5). Interestingly, RUNX2, MBNL1, JMJD1C,
SENP6, MEF2C, and ZEB2 are also hypomethylated in MLL-FP
samples compared to either normal cells or other leukemias (Fig-
ureS5B;not shown).Although thesedatashowthatsomeMLL-FP
spreading targets can individually havean important role in human
leukemias, theredoesnot seem tobe a single key set of spreading
targets that are necessarily found in all MLL-FP samples. Howev-
er, taken in total, the data show that MLL-FP spreading is an indi-
cator of particularly significant MLL-FP activity.
Spreading CorrelateswithMenin andMLL-AF4Complex
Components
To better understand MLL-FP spreading, we analyzed whether
spreading is related to other MLL-AF4 complex components488 Cell Reports 18, 482–495, January 10, 2017(Figure 5A). When all MLL-AF4 spreading targets were sorted
by length, the ChIP-seq signal of MLL(N) and AF4(C) generated
a characteristic curve shape (Figure 5B, panels 1 and 2). Interest-
ingly, MLL-AF4 spreading is punctuated by uCpG sites, with the
beginning and end of spreading domains demarcated by uCpG
sites (Figures 5A and 5B, panel 3). This indicates a role for the
CXXC domain in stabilizing spreading and agrees with the hypo-
methylation observed at spreading MLL-AF4 targets in patients
(Figure S5B). This is an important role for the CXXC domain
within the context of MLL-AF4 because neither KDM2B nor
CFP1 showed the same spreading pattern, even though they
both bind to uCpGs (Figures 5A and S6A). The majority of
uCpG regions under spreading peaks were within 1–2 kb of
each other and rarely exceeded 4 kb, with 7 kb being the greatest
distance observed (Figure S6B). Therefore, the proximity of
uCpG sites to each other under the spreading peaks appears
to be important and may be a limiting factor in determining the
degree of spreading. If true, this also suggests that spreading
may be non-random, and only genes with a clustered uCpG
landscape downstream of their promoter are amenable to
spreading.
Spreading was not simply a result of an association with basal
transcription factors because neither RNAPII nor members of
PAFc showed the same spreading pattern; instead, they
extended beyond the spreading domain to the end of the gene
(Figures 1C, 5A, and S6C). Conversely, both Menin and ENL dis-
played identical spreading patterns to MLL-AF4 (Figures 1C, 5A
and 5B, panels 4 and 5). Our observation that Menin knock-
downs reduce MLL-AF4 binding at spreading gene targets (Fig-
ures 2E–2G) supports the idea that there is a role forMenin in sta-
bilizing spreading. In conclusion, we envisage a model whereby
CXXC-mediated weak binding of the fusion protein at low-CG
density uCpG sites in the gene body can be stabilized by
CXXC-mediated recruitment to the CG-rich uCpGs at promoters
(Figure 5C). However, this depends on the weak binding sites
occurring in close proximity to the promoter and each other,
with Menin or ENL facilitating stabilization through a bridging
mechanism (Figure 5C).
Spreading MLL-AF4 Represents a Subset of Broad
H3K4me3 Distinct from Super-Enhancers
Several recent studies have characterized broad binding chro-
matin domains as markers of functional significance, including
super-enhancers (Love´n et al., 2013; Whyte et al., 2013) and
broad regions of H3K4me3 (Benayoun et al., 2014). Whereas
genes associated with super-enhancers were shown to correlate
with increased expression, genes marked by broad H3K4me3
showed an increase in transcriptional consistency, i.e., less vari-
ation in transcription rate between replicates as determined by
RNA-seq and nascent RNA-seq, as well as an increase in gene
expression (Benayoun et al., 2014). Here, we wanted to deter-
mine whether MLL-AF4 spreading domains were related to
either super-enhancers or broad H3K4me3 peaks.
First, we characterized super-enhancers and broad H3K4me3
domains in SEM cells using the same criteria as the original
studies (Figures S6D–S6G). Almost all regions of spreading
MLL-AF4 were distinct from super-enhancers, but the majority
(87%) of spreading MLL-AF4 gene targets were a subset of
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Figure 4. MLL-FP Spreading Occurs in Multiple in MLL Leukemias
(A) Spreading MLL-AF6 peaks were defined as peaks that extend greater than 4 kb from the TSS into the gene body without going beyond the end of the gene.
Using these criteria, 47 spreading MLL-AF6 peaks were identified in ML-2 cells (Table S2).
(legend continued on next page)
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broad H3K4me3 gene targets (Figure 5D). Despite being distinct
from super-enhancers, spreading MLL-AF4 correlated with
MED1 and BRD4 binding as well as H3K27Ac (Figure 5E, panels
1–3). The major difference between MLL-AF4 spreading
domains and super-enhancers was the lack of H3K4me1 enrich-
ment; instead, spreading overlaps with H3K4me3 and
H3K79me2 (Figure 5E, panels 4–6).
Similar to past work (Benayoun et al., 2014), gene targets of
the 5% broadest H3K4me3 peaks in SEM cells showed a signif-
icant increase in transcriptional consistency compared to genes
marked by the remaining 95% of H3K4me3 peaks (p < 0.0001,
Mann-Whitney U test, Figure S6H). As a whole, gene targets of
MLL-AF4 showed a significant increase in transcriptional consis-
tency compared to H3K4me3-marked genes (p < 0.0001, Mann-
Whitney U test; Figure S6I), suggesting that maintaining gene
regulation within narrow limits could be an important property
of MLL-AF4 controlled gene expression crucial for the leukemia.
However, spreading MLL-AF4 gene targets did not show
increased transcriptional consistency compared to all MLL-AF4
gene targets (Figure S6I); thus, this was not a feature specific to
spreading. Based on the signature of histone marks and protein
associations, spreading MLL-AF4 represents a hybrid of broad
H3K4me3 domains and super-enhancers, with transcriptional
properties such as high expression (Figure 3C) more similar to
super-enhancers.
Gene Targets of Spreading MLL-AF4 Display Increased
Sensitivity to DOT1L Inhibition
If it is possible to target spreading MLL-AF4 target genes, it is
likely that this would have a strong and specific effect on the in-
hibition of leukemia maintenance. Because spreading MLL-AF4
targets are marked with high levels of H3K79me2 (Figure 3D),
we wanted to determine whether they are particularly sensitive
to the DOT1L inhibitor EPZ-5676 (Daigle et al., 2013). Treatment
of SEM cells with 2 mMEPZ-5676 for 7 days produced an almost
complete loss of the H3K79me3 mark for all genes tested (Fig-
ure S7A). Using nascent RNA-seq, we identified 2,462 downre-
gulated genes, 84% of which were marked by H3K79me2 (Fig-
ure 6A) and that included a number of spreading targets (e.g.,
CDK6; Figure 6B). As a group, over 50% of spreading targets
were downregulated following EPZ-5676 treatment compared
to only 16% of non-spreading MLL-AF4 targets and 23% of
H3K79me2-marked genes (p < 0.0001, two-tailed Fisher’s exact
test; Figure 6C). Furthermore, spreading MLL-AF4 targets were(B) Composite binding plot of H3K79me2ChIP-seq reads at the TSS of gene targe
(C) Example ChIP-seq tracks of MLL(N) in MLL-FP and germline MLL cell lines.
(D) Heatmaps ofMLL(N) ChIP-seq reads fromdifferentMLL-FP cell lines aswell as
spreading across a 10-kb window. Scale bar represents tags per base pair per 1
(E) Example ChIP-seq tracks of MLL(N) showing spreading in MLL-AF4 patient c
blood (middle) and fetal bone marrow (bottom).
(F) Heatmaps showing MLL(N) ChIP-seq reads from the experiments in (E); scale
(G) Venn diagram showing the overlap between gene targets of spreading MLL(N
(H) CPEB2,MBNL1, and RUNX2 are overexpressed in MLL-AF4 and other MLL-F
dot indicates an individual patient sample. Data are taken from an ECOG E299
difference compared to MLL-AF4, and pink asterisk (*) indicates a significant diffe
[1], and MLL-EPS15 [1]). ***p < 0.001, **p < 0.01, *p < 0.05. A two-tailed Wilcoxon
are listed in Table S5.
See also Figures S4 and S5.
490 Cell Reports 18, 482–495, January 10, 2017among those that showed the greatest downregulation, even
compared to genes that had similar levels of high expression (Fig-
ure 6D). Spreading MLL-AF4 gene targets were also significantly
more downregulated in response to EPZ-5676 compared to non-
spreading MLL-AF4 gene targets (p < 0.0001, Mann-Whitney U
test; Figure 6E). Therefore, spreading MLL-AF4 targets are
among the most sensitive to treatment with EPZ-5676 when
compared to all other genes. Using a randomly selected group
of genes with levels of H3K79me2 similar to those of spreading
MLL-AF4 targets (Figure S7B), we also found that spreading
MLL-AF4 targets were significantly more downregulated after
EPZ-5676 treatment (Figure S7C, top and bottom; p < 0.0001
and p < 0.01, respectively; Mann-Whitney U test). Therefore,
genesmarked by spreadingMLL-AF4 show increased sensitivity
to EPZ-5676 through a mechanism not simply determined by
high levels of H3K79me2. Interestingly, spreading targets that
overlapped with either broad H3K4me3 or super-enhancers
were significantly more sensitive to DOT1L inhibition than
spreading MLL-AF4 targets alone (Figure S7D). This indicates
that there are further subdivisions of activity within spreading tar-
gets themselves, something that may explain recent results look-
ing at DOT1L and BRD4 cooperation (Gilan et al., 2016).
As well as being particularly sensitive to a loss of
H3K79me2/3, spreading MLL-AF4 gene targets were signifi-
cantly downregulated compared to non-spreading and non-
MLL-AF4 targets by MLL-AF4 siRNA treatment (p < 0.0001,
two-tailed Mann Whitney U test; Figure 6F). Therefore, the
increased gene expression observed at MLL-AF4 spreading tar-
gets is significantly linked to both MLL-AF4 and H3K79me2 and
is more likely to be downregulated by DOT1L inhibition.
Sensitivity of Spreading Gene Targets Provides a
Rationale for Combination Therapy Using DOT1L
Inhibitors
It seems unlikely that a single drug alone will be effective in treat-
ing MLL-AF4 leukemias. Even among MLL-AF4 spreading tar-
gets, some gene targets have an increased sensitivity to a loss
of H3K79me2 (Figures 7A and 7B; Table S6). We recently
showed that the BCL-2-specific protein inhibitor ABT-199 syner-
gizes with DOT1L inhibitors (Benito et al., 2015), potentially
because BCL-2 protein levels are not strongly affected by
DOT1L inhibitor concentrations that affect more sensitive targets
such as CDK6 or BCL11A (Figure 7B). Because Menin is partly
responsible for spreading (see Figures 2E–2G and 5A–5C), thets of spreadingMLL-AF6 (red) and non-spreadingMLL-AF6 (blue) inML-2 cells.
wild-typeMLL in SEMcells and in non-MLLr cell lines. Red dotted line indicates
07 reads.
ells (top) compared to wild-type MLL in mononuclear cells derived from cord
and red line as in (D).
) ChIP-seq several MLLr cell lines.
P patients compared to different patient samples and normal pre-B cells. Each
3 clinical trial (Geng et al., 2012). Dark red asterisk (*) indicates a significant
rence compared to the MLL-FP group (which includes MLL-ENL [6], MLL-AF9
test was used to calculate p values, and p values for the different comparisons
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Figure 5. Spreading Correlates with Members of the Menin:LEDGF and Super-Elongation Complexes
(A) Example ChIP-seq tracks at SUPT3H in SEM cells.
(B) Heatmap of MLL-AF4, Bio-Cap, Menin, and ENL signal at all 149 spreading MLL-AF4 targets, ordered by length of spreading peak. Scale bar represents tags
per bp per 107 reads.
(C) Schematic showing a proposed model for spreading across uCpG regions by MLL-FPs. (i) In the absence of promoter-bound MLL-AF4, CXXC-mediated
recruitment of the fusion protein to uCpG-poor regions in the gene body are not stabilized. (ii) Stable CXXC-mediated recruitment to uCpG-rich promoter regions
can stabilize nearby MLL-AF4 recruitment at gene body uCpG regions due to common interactions with complex members such as Menin and ENL, whereas
distal recruitment events remain unstable. (iii) Because other CXXC proteins, such as KDM2B, do not interact with complex member such as Menin or ENL,
promoter-bound KDM2B is not sufficient to stabilize neighboring CXXC-mediated recruitment to CpG-poor uCpG regions in the gene body.
(D) Venn diagram showing the overlap between gene targets of super-enhancers, broad H3K4me3 peaks, and spreading MLL-AF4, in SEM cells.
(E) Heatmap showing ChIP-seq reads of the components indicated at all 149 spreading MLL-AF4 gene targets in SEM cells; scale bar as in (B).
See also Figure S6.use of Menin inhibitors represents another way to target sensi-
tive MLL-AF4 spreading genes (see Figure S7E). In an extension
of our earlier work, we find that there is a strong synergy between
ABT-199 and the DOT1L inhibitors EPZ5676 and SGC0946, as
well as a strong synergistic interaction between the Menin inhib-itor MI-503 (Borkin et al., 2015) and ABT-199 (Figures 7C–7F;
combination index [CI] < 1; calculations as described in Milella
et al. [2002]). Thus, carefully choosing different drug combina-
tions may increase their effectiveness at disrupting MLL-FP
leukemic growth.Cell Reports 18, 482–495, January 10, 2017 491
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Figure 6. Spreading MLL-AF4 Targets
Show Increased Sensitivity to DOT1L Inhibi-
tion
(A) Venn diagram showing an overlap between
H3K79me2-marked genes and upregulated and
downregulated genes in SEM cells following
treatment with 2 mM EPZ-5676.
(B) Example ChIP-seq tracks atCDK6 and nascent
RNA-seq in control (0 mM) and 2 mM EPZ-5676-
treated SEM cells.
(C) Pie charts showing the proportion of genes that
are significantly downregulated (blue), upregu-
lated (red), or remain unchanged (gray), among
H3K79me2-marked genes (left), non-spreading
MLL-AF4 gene targets (center), and spreading
MLL-AF4 gene targets (right), following treatment
of SEM cells with 2 mM EPZ-5676. ****p < 0.0001,
Fisher’s exact test.
(D) Smear plot showing the fold change in gene
expression of all genes in SEM cells following
treatment with 2 mM EPZ-5676 compared to their
expression level (CPM). Black, non-significant
change in gene expression; red, differentially ex-
pressed gene; green, spreading MLL-AF4 gene
targets.
(E) Box-and-whisker plot showing the median and
IQ range of fold change in expression of all
significantly downregulated gene targets of non-
spreading MLL-AF4 (red) compared to spreading
MLL-AF4 (blue), after 2 mM EPZ-5676 treatment in
SEM cells. ****p < 0.0001, Mann-Whitney U test.
(F) Box-and-whisker plot showing the median and
IQ range of fold change in expression of all
significantly affected spreading MLL-AF4 (blue),
non-spreading MLL-AF4 (red), and non-MLL-AF4
gene targets following siRNA-mediated knock-
down of MLL-AF4 in SEM cells. ****p < 0.0001,
Mann-Whitney U test.
See also Figure S7.DISCUSSION
In this study, we have found that uCpGs strongly correlate with
the highest occupancy of MLL-AF4 binding and that MLL-AF4
and Menin co-stabilize each other’s binding to gene targets.
This mirrors recent findings of co-dependent stabilization be-
tween wild-type MLL and LEDGF (Zhu et al., 2016), which would
suggest an independent role for LEDGF in wild-type MLL func-
tion, as previous reports indicate that Menin and wild-type
MLL regulate distinct gene targets (Li et al., 2013). Zhu et al.
have also shown that loss of LEDGF actually increases MLL-FP
recruitment (Zhu et al., 2016), which is partly supported by our
Ledgf knockdown experiment (Figure S2G). We have also shown
that there is no direct connection between MLL-AF4 recruitment
and PAFc, suggesting that past observations of MLL-FP depen-
dence on PAFc (Milne et al., 2010; Muntean et al., 2010) may
have been due to indirect effects, or perhaps PAFc is only
required for binding of MLL-FPs at specific gene targets such
as HOXA9.
Previous studies have indicated that MLL-FP binding can be
associated with broad chromatin domains (Bernt et al., 2011;
Guenther et al., 2008) or divided into two classes, with 50 bind-
ing indicating a dependence on H3K79me2 (Garcia-Cuellar492 Cell Reports 18, 482–495, January 10, 2017et al., 2016). Our results suggest that it is not the presence of
MLL-AF4 and H3K79me2/3 that is most predictive of a depen-
dence on H3K79me2, but the presence of MLL-AF4 spreading.
Our observations also show that spreading strongly correlates
with Menin and ENL binding and occurs across uCpG land-
scapes in the gene body that are within close proximity to the
gene promoter. Unmethylated CpG regions in gene bodies
typically display a relatively low CG density, which is possibly
why we do not observe other CXXC proteins binding in the
gene body. Therefore, spreading of MLL-FPs may be made
possible by Menin/ENL-mediated stabilization at gene body
uCpG regions where uCpG density is too low for a strong
CXXC-uCpG interaction. Although wild-type MLL can also
interact with Menin, a co-operation with fusion partner proteins
such as ENL may generate complexes that permit MLL-FP
dimerization (Mueller et al., 2007; Yokoyama et al., 2010) and
through this mechanism create a spreading domain of MLL-FP
that is anchored by CXXC-uCpG interactions in close
proximity to each other, something that is unavailable to wild-
type MLL.
It is unknown whether an ability to spread into the body of
particular gene targets drives higher expression and initiates
progression of leukemia or whether these gene targets are
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Figure 7. Sensitivity of Spreading Gene Tar-
gets Provides a Rationale for Combined
Therapy Using DOT1L Inhibitors
(A) Venn diagram showing the overlap of
spreading MLL-AF4 gene targets that are down-
regulated as measured by nascent RNA-seq
following 0.5 mM (blue), 1 mM (red), and 2 mM
(green) EPZ-5676 treatment.
(B) Western blot showing the protein expression of
several spreadingMLL-AF4 targets and controls in
the presence of control, 0.5, 1, or 2 mM EPZ-5676
treatments. Blue and red boxes relate to treatment
colors in (A) that led to the lowest level of treatment
that resulted in reduced gene transcription.
(C–E) A cell viability assay of SEMK2 cells treated
with a DMSO control, different concentrations of
ABT-199 (320, 160, 80, 40, 20, 10, and 5 nM, and
DMSOcontrol) alone, or in combination with a 1:10
ratio of either EPZ5676 (C), SGC0946 (D), or MI503
(E) (3,200, 1,600, 800, 400, 200, 100, and 50 nM,
and DMSO control).
(F) A tabular summary of the combination index for
the different drug treatments calculated as in
Milella et al. (2002).already highly expressed and the active chromatin landscape is
simply a pre-requisite for facilitating spreading. Nevertheless, in
the context of these remaining questions, our study has revealed
that spreading of MLL-AF4 defines the expression of a subset of
genes that are important for leukemia and are characterized by
gene activation that is predictive of a poor prognosis. These
target genes are particularly sensitive to DOT1L inhibition, which
provides a new molecular rationale for the specificity of DOT1L
or Menin inhibition in MLL-AF4 leukemias, and the possibility
of combining this with drugs that target less sensitive spreading
targets such as those that target BCL-2.
EXPERIMENTAL PROCEDURES
Cell Lines, Cultures, and Drug Treatment Studies
Cell lines, culturemethods, and drug treatment protocols used in this study are
listed in Supplemental Experimental Procedures. CB was collected under the
auspices of a National Research Ethics Service-approved study with written
informed consent. Human fetal bone samples were obtained through the Hu-
man Development Biology Resource (http://www.hdbr.org).
Western Blot Analysis
Western blot analysis was performed as previously described (Wilkinson et al.,
2013). Antibodies used for western blot analysis are listed in Supplemental
Experimental Procedures.Cell RChIP Assays and ChIP-Seq
ChIP and ChIP-seq experiments were performed
as described in Supplemental Experimental Pro-
cedures and as previously described (Benito
et al., 2015; Wilkinson et al., 2013).
TetR Recruitment System
For the TetR recruitment assay, we used the previ-
ously engineered Tet-operon (TetO) mESC line
(Blackledge et al., 2014). MLL-AF4, Menin, and
PAF1 cDNA were inserted downstream of the
FS2-TetR coding sequence in the original pCAGF-S2TetR vector, by ligation-independent cloning (LIC). Plasmids were trans-
fected into TetOmESCs using Lipofectamine 2000, and clones stably express-
ing TetR fusions were selected using puromycin (1 mg/mL), orMLL-AF4 cDNA
was transiently transfected into mESCs at 60%–70% confluency using Lipo-
fectamine 2000. Cells were collected 24 hr after transfection.
Gene Targets and Spreading Peaks
ChIP-seq peaks were called as described in Supplemental Experimental Pro-
cedures. Gene targets were defined as any gene where the transcription start
site (TSS) overlapped directly with a peak. A peak was classed as spreading if
it overlapped the TSS of a gene and extended over 4 kb from the TSS into the
gene body without going beyond the transcription end site (TES) of the gene. If
a peak exhibited spreading at two different genes (or isoforms with different
TSS co-ordinates), both spreading-gene pairs were kept.
Nascent RNA-Seq
Nascent RNA-seq and gene expression analysis was performed as described
in Supplemental Experimental Procedures.
Survival Analysis
Clinical datasets and survival analyses are detailed in Supplemental Experi-
mental Procedures.
Statistics
Data were analyzed using Fisher’s exact test, Wilcoxon test, and Mann-Whit-
ney U test, where appropriate. Results were deemed significant if p < 0.05. Un-
less otherwise indicated, data are shown as mean ± SD. This paper analyzedeports 18, 482–495, January 10, 2017 493
datasets from GEO: GSE13313, GSE28460, GSE29130, GSE34861,
GSE73528, GSE74812, and GSE84116; and ArrayExpress: E-MTAB-3593
(for a detailed list of datasets, see Table S7).
ACCESSION NUMBERS
The accession number for the datasets reported in this paper is GEO:
GSE83671.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and seven tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.12.054.
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